

Mechanisms of Resistance to Crizotinib in Patients with *ALK* Gene Rearranged Non–Small Cell Lung Cancer

Robert C. Doebele¹, Amanda B. Pilling¹, Dara L. Aisner², Tatiana G. Kutateladze³, Anh T. Le¹, Andrew J. Weickhardt¹, Kimi L. Kondo⁴, Derek J. Linderman⁶, Lynn E. Heasley⁵, Wilbur A. Franklin², Marileila Varella-Garcia¹, and D. Ross Camidge¹

Abstract

Purpose: Patients with anaplastic lymphoma kinase (*ALK*) gene rearrangements often manifest dramatic responses to crizotinib, a small-molecule *ALK* inhibitor. Unfortunately, not every patient responds and acquired drug resistance inevitably develops in those who do respond. This study aimed to define molecular mechanisms of resistance to crizotinib in patients with *ALK*⁺ non–small cell lung cancer (NSCLC).

Experimental Design: We analyzed tissue obtained from 14 patients with *ALK*⁺ NSCLC showing evidence of radiologic progression while on crizotinib to define mechanisms of intrinsic and acquired resistance to crizotinib.

Results: Eleven patients had material evaluable for molecular analysis. Four patients (36%) developed secondary mutations in the tyrosine kinase domain of *ALK*. A novel mutation in the *ALK* domain, encoding a G1269A amino acid substitution that confers resistance to crizotinib *in vitro*, was identified in two of these cases. Two patients, one with a resistance mutation, exhibited new onset *ALK* copy number gain (CNG). One patient showed outgrowth of epidermal growth factor receptor (*EGFR*) mutant NSCLC without evidence of a persistent *ALK* gene rearrangement. Two patients exhibited a *KRAS* mutation, one of which occurred without evidence of a persisting *ALK* gene rearrangement. One patient showed the emergence of an *ALK* gene fusion–negative tumor compared with the baseline sample but with no identifiable alternate driver. Two patients retained *ALK* positivity with no identifiable resistance mechanism.

Conclusions: Crizotinib resistance in *ALK*⁺ NSCLC occurs through somatic kinase domain mutations, *ALK* gene fusion CNG, and emergence of separate oncogenic drivers. *Clin Cancer Res*; 18(5); 1472–82. ©2012 AACR.

Introduction

Non–small cell lung cancer (NSCLC) is increasingly recognized as a heterogeneous set of diseases at the molecular level and these differences can drive therapeutic decision making (1–3). Transforming rearrangements of the anaplastic lymphoma kinase (*ALK*) gene were initially identified in anaplastic large cell lymphoma (4). In 2007, an *ALK* gene rearrangement (*ALK*⁺) in which the 5′ end of the echinoderm microtubule-associated protein-like 4

(*EML4*) gene was fused to the 3′ portion of *ALK* was identified in NSCLC (5).

Recently, crizotinib has gained U.S. Food and Drug Administration approval for the treatment of *ALK*⁺ NSCLC. Crizotinib approval was based, in part, on data from the phase I clinical trial which showed an overall response rate of 57% and a probability of progression-free survival at 6 months of 72% (6). Unfortunately, some *ALK*⁺ patients will not derive any benefit from crizotinib (intrinsic resistance), whereas patients who initially derive benefit later develop resistance (acquired resistance).

Several groups have explored molecular mechanisms of acquired resistance in a comparable clinical scenario involving resistance to epidermal growth factor receptor (*EGFR*)–tyrosine kinase inhibitors (TKI) in *EGFR* mutant NSCLC (7–9). The most common mechanism noted in these patients involves a change in the target of the drug, specifically a second *EGFR* mutation, T790M, that alters the binding kinetics of the reversible TKIs to the target molecule (10). In addition, clinical examples of second oncogenic drivers within the same cell harboring the *EGFR* mutation, notably *MET* gene amplification, bypassing the block caused by the TKI have also been reported (8, 11).

Authors' Affiliations:¹Division of Medical Oncology, Department of Medicine, Departments of ²Pathology, ³Pharmacology, ⁴Radiology, and ⁵Craniofacial Biology, and ⁶Division of Pulmonology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colorado

Note: Supplementary data for this article are available at Clinical Cancer Research Online (<http://clincancerres.aacrjournals.org/>).

Corresponding Author: Robert C. Doebele, University of Colorado Anschutz Medical Campus, MS 8117, 12801 E. 17th Avenue, Aurora, CO 80209. Phone: 303-724-2980; Fax: 303-724-3889; E-mail: robert.doebele@ucdenver.edu

doi: 10.1158/1078-0432.CCR-11-2906

©2012 American Association for Cancer Research.

Translational Relevance

Crizotinib is an orally bioavailable, small-molecule tyrosine kinase inhibitor that was approved by the U.S. Food and Drug Administration in 2011 for use in patients with anaplastic lymphoma kinase (*ALK*) FISH⁺ non-small cell lung cancer (NSCLC). Crizotinib provides significant clinical benefit for ALK⁺ NSCLC. Unfortunately, it is expected that not all ALK⁺ patients will benefit and those patients who do respond will eventually experience resistance of their NSCLC to crizotinib. In the same way that using targeted therapies in patients with molecularly defined cancer has been successful, it is anticipated that understanding the molecular mechanisms of resistance to targeted therapies in cancer will lead to therapeutic strategies to overcome resistance in the same population of patients. Here, we describe the molecular mechanisms of resistance to crizotinib in a series of patients with ALK⁺ NSCLC.

Isolated case reports have recently identified mutations in ALK⁺ NSCLC that occur after crizotinib therapy (12, 13). However, the frequencies with which these and any other mechanisms of resistance occur remain unknown. Here, we report on the clinical and molecular details of 14 patients with ALK⁺ NSCLC with intrinsic or acquired resistance to crizotinib.

Materials and Methods

Patients

Patients with ALK⁺ NSCLC, who were treated on a phase I study of crizotinib, were considered for rebiopsy upon progression on crizotinib therapy (6). Patients were consented for tissue banking under the University of Colorado Lung Cancer SPORE tissue banking protocol and all research tests were conducted under Institutional Review Board approval. Formalin-fixed, paraffin-embedded (FFPE), fresh-frozen and/or tissue for the initiation of cell lines were collected from each patient as deemed safe and feasible by the interventional radiologist/pulmonologist. Diagnostic sampling was prioritized over research sampling in each case. No sample size was prespecified and the analysis conducted was descriptive.

ALK molecular testing

ALK positivity was ascertained by FISH using ALK break-apart probes [Vysis LSI ALK (2p23) Dual Color, Break Apart Rearrangement Probe; Abbott Molecular]. The FISH assays and analyses were conducted as described previously with minor modifications (14). Using the ALK break-apart probe, 3' (red) and 5' (green) signals physically separated by ≥ 2 signal diameters were considered split. Specimens were considered positive for ALK rearrangement if more than 15% of tumor cells showed split signals or single red signals. Copy number of ALK rearrangement was based on determination of the mean of split and isolated red signals

per tumor cell (15). At least 100 tumor cells were analyzed per specimen.

RNA from either FFPE or frozen tissue was processed using the RecoverAll Total Nucleic Acid Isolation Kit from Ambion. Reverse transcriptase PCR (RT-PCR) was carried out using the SuperScript III One-Step RT-PCR System with Platinum Taq DNA Polymerase from Invitrogen with primers to *EML4-ALK*. PCR products were either resolved on an agarose gel or analyzed with a Bioanalyzer from Agilent Technology, excised, and purified using Wizard SV Gel and PCR Clean Up Kit from Promega, then sequenced as described later. Primers used for RT-PCR or multiplexed RT-PCR of the *EML4-ALK* gene fusion transcript are listed in Supplementary Table S1 or have been previously described (16, 17).

EGFR, KRAS, ALK, and short tandem repeat genotyping

Genomic DNA was isolated from manually microdissected FFPE tumor samples using the QIAamp FFPE DNA Isolation Kit from Qiagen. Samples were PCR amplified using custom primer sets for exon 2 of *KRAS*, exons 19 to 21 of *EGFR*, or exons 21 to 25 of *ALK* (see Supplementary Table S1 for primers) and directly sequenced using the ABI Big Dye Thermocycle Sequencing Kit and analyzed on an ABI 3730 DNA Sequencer (16). Mutation analysis was assisted by the use of Mutation Surveyor software v3.97-4.0.0 from SoftGenetics. The reference sequence for ALK sequence comparison used was NM_004304.4, for *EML4* NM_019063.3, for *EGFR* NM_005228.3, and for *KRAS* NM_004985.3. We have used the colloquial single letter amino acid substitution for mutations described here rather than the official nomenclature for simplicity (e.g., L1196M rather than p.Leu1196Met).

The SNaPshot assay for evaluation of multiple oncogenic mutations in *APC*, *AKT1*, *BRAF*, *CTNNB1*, *EGFR*, *FLT3*, *JAK2*, *KIT*, *KRAS*, *MAP2K1* (*MEK1*), *NOTCH1*, *NRAS*, *PIK3CA*, *PTEN*, and *TP53* was conducted by amplification using 13 multiplexed PCR reactions followed by single nucleotide base extension reactions. The products were separated by capillary electrophoresis and analyzed using GeneMapper 4.0 as has been previously described (18). To confirm patient identity across multiple samples in select cases, short tandem repeat analysis was conducted on extracted genomic DNA using the AmpFISTR Identifier PCR Amplification Kit (Applied Biosystems).

Cell lines and reagents

Primary cell lines were derived from patients by placing fresh tumor tissue into sterile tissue culture dishes and culturing in RPMI supplemented with 10% FBS. A new cell line, CUTO-1 (Colorado University Thoracic Oncology), derived from a tumor biopsy sample of patient #10 is described here. Ba/F3 cells (kindly provided by James DeGregori) were cultured in RPMI supplemented with 10% FBS and 1 ng/mL of interleukin (IL)-3 from R&D Systems. 293T human embryonic kidney cells and NIH3T3 mouse fibroblast cells were obtained from American Type Culture Collection and grown in Dulbecco's Modified

Eagle's Media supplemented with 5% FBS. NCI-H3122 and NCI-H2228 (kindly provided by John D. Minna and Adi F. Gazdar, University of Texas Southwestern, Dallas, TX) were grown in RPMI with 10% FBS.

Mouse monoclonal against total ALK (#3791), rabbit polyclonal against phosphorylated ALK Tyr 1278/1282/1283 (#3983), mouse monoclonal against AKT (#2920), mouse monoclonal against total ERK p42/44 (#9107), rabbit polyclonal against phosphorylated ERK Thr202/Tyr204 (#9101), mouse monoclonal against total STAT3 (#9139), and rabbit polyclonal against phosphorylated STAT3 Tyr705 (#9145) were purchased from Cell Signaling Technology. Rabbit polyclonal antibodies against phosphorylated AKT Ser473 (sc-135651) and mouse monoclonal antibodies against α -tubulin (#sc-8035) were purchased from Santa Cruz Biotechnology. IRDye 680LT- and 800CW-conjugated goat anti-mouse secondary antibodies were purchased from LI-COR Biotechnology. PF-02341066 (crizotinib) was kindly provided by Pfizer and dissolved in dimethyl sulfoxide for experiments.

Lentiviral constructs and transduction

The *EML4-ALK* gene fusion containing *EML4* exons 1–6 variant and *ALK* exons 20–29 (E6a;A20) was cloned by RT-PCR from mRNA isolated from the cell line, H2228, and inserted into the lentiviral expression plasmid, pCDH-MCS1-EF1-puromycin from Systems Biosciences. Point mutations were introduced into the *EML4-ALK* fusion gene using the QuikChange II XL Site-Directed Mutagenesis Kit from Agilent Technology (see Supplementary Table S1 for primers). Lentiviral transduction of Ba/F3, NIH3T3, and H3122 was carried out as previously described (19).

Immunoblotting

Immunoblotting was conducted as previously described with minor modifications (20). Briefly, cells were lysed in modified radioimmunoprecipitation assay (RIPA) buffer supplemented with Halt Protease and Phosphatase Inhibitor Cocktail purchased from Thermo Scientific. Total protein was separated by SDS-PAGE, transferred to nitrocellulose, and stained with the indicated primary antibodies. Protein detection was achieved by imaging with an Odyssey Imager and Odyssey Version 3.0 image analysis software from LI-COR Biotechnology.

Proliferation and soft agar colony assays

Proliferation of Ba/F3 cells was measured using the Cell-Titer 96 Aqueous Proliferation Assay from Promega according to the manufacturer's instructions. Briefly, cells were seeded into 96-well plates 24 hours before drug treatment, and proliferation was measured 72 hours after treatment. The absorbance at 490 nm was measured in 96-well plates using a Microplate Reader from Molecular Devices. The IC_{50} values were calculated using Prism v5.02 from GraphPad Software.

To measure anchorage-independent growth and its inhibition by crizotinib, NIH3T3 cells expressing nonmutated or mutated cDNAs encoding *EML4-ALK* (E6a;A20) were

suspended in media containing 0.4% agar and plated in 6-well plates containing media and 0.5% agar per well. Wells were fed every 3 days with media with the indicated concentrations of crizotinib and incubated for 14 days. Colonies were stained for 24 hours with nitroblue tetrazolium and photographs were taken for colony quantification with MetaMorph Software from Molecular Devices.

Results

Rebiopsy of patients after progression on crizotinib

Fourteen *ALK*⁺ patients underwent 15 rebiopsy procedures after radiologic evidence of disease progression/lack of response on crizotinib (Fig. 1B and Supplementary Fig. S1A and Table S1). Typically, diagnostic biopsies were used as the pre-crizotinib (baseline) sample for comparison purposes within this study. Two patients were biopsied after disease progression at the first evaluation on crizotinib (intrinsic resistance). Twelve patients underwent biopsy after initial benefit then progression (acquired resistance) after median time on crizotinib of 8.9 months (range, 3.8–21.1 months). One patient underwent 2 separate biopsy procedures postinitiation of crizotinib, one after a lack of response (stable disease), followed by biopsy of a separate lesion after disease progression per Response Evaluation Criteria in Solid Tumors (RECIST; version 1.0).

Three patients (#1–3) failed to yield evaluable material from their biopsy. Frozen tumor tissue was collected from 4 patients and FFPE was collected on 11 patients. All 11 patients with evaluable tissue underwent repeat *ALK* FISH testing (Table 1). Attempts to propagate a cell line occurred for 8 patients. Currently, only one cell line, from patient #10, is propagating at a rate permitting evaluation.

ALK domain mutations as a resistance mechanism to crizotinib

Acquired mutations clustering around the kinase domain ATP-binding site are a well-recognized mechanism of acquired resistance to TKIs (7, 21, 22). We therefore conducted direct sequencing of *ALK* exons 21–25, encoding the kinase domain. Four patients (#4–7) were found to have point mutations in the kinase domain of *ALK* (Table 2). None of these patients had sufficient tissue in their pre-crizotinib biopsy to determine if these mutations were detectable before crizotinib therapy. Patients #4 and #5 were found to have the previously described mutation encoding the L1196M substitution (data not shown). Two patients (#6 and 7) showed the presence of a novel mutation that encodes a G1269A substitution (Table 2, Supplementary Fig. S2A, and data not shown).

A multiplexed RT-PCR assay for *EML4-ALK* was carried out when possible to determine the variant of the *ALK* gene fusion and we successfully confirmed the presence of *EML4-ALK* in 4 patients. Interestingly, patient #7 showed a new variant fusing exon 6 of *EML4* to exon 19 of *ALK* (E6;A19; Table 2, Supplementary Fig. S3). An *EML4-ALK*-specific RT-PCR was carried out on mRNA to selectively amplify and sequence the expressed transcripts of *EML4-ALK* (Supplementary Fig. S3A).




Figure 1. Identification and characterization of a novel *ALK* domain mutation in patients. Surface (A) and ribbon (B) models of the *ALK* domain in complex with crizotinib (PDB 2XP2). Insets to the right represent a magnified view of the ATP-binding pocket where crizotinib is located. A and B were generated using the PyMol molecular graphics system. C, Ba/F3 cells expressing wild-type *EML4-ALK* (E6;A20) or the same *EML4-ALK* construct with the specified *ALK* domain mutations or empty vector were treated with the indicated concentration of crizotinib and viable cells were measured after 72 hours and then plotted relative to untreated controls. Ba/F3 cells expressing empty vector were grown in the presence of IL-3. D, SDS-PAGE and immunoblotting analysis to detect the indicated proteins in cell lysates from NIH3T3 cells expressing wild-type *EML4-ALK* (E6;A20) and *EML4-ALK* (E6;A20) G1269A treated with the indicated doses of crizotinib for 5 hours. NIH3T3 with empty vector (EV) are also shown as a control. E, quantitation of Western blot analysis in D is graphically represented using LI-COR image analysis software. F, Ba/F3 cells expressing wild-type *EML4-ALK* (E6;A20), or the same *EML4-ALK* construct with the specified *ALK* domain mutations or empty vector (with and without IL-3) were plated and viable cells were measured at the indicated time points and plotted. WT, wild type.

The amino acid substitutions encoded by the observed mutations were mapped onto the crystal structure of the *ALK* domain (Fig. 1A and B; ref. 23). All of the mutations detected in this series were found in, or near, the long narrow groove that comprises the binding pocket for both ATP and crizotinib. The L1196M substitution has been previously described in a patient with crizotinib resistance

and is homologous to the gatekeeper mutations identified in *BCR-ABL* (T315I) and *EGFR* (T790M; refs. 7, 12, 21).

The Gly1269 residue is positioned at the end of the narrow ATP-binding pocket of *ALK* (Fig. 1A and B). Substitution of Gly1269 with the larger Ala residue would be expected to reduce binding of crizotinib due to steric hindrance. To determine whether the G1269A substitution

Table 1. ALK FISH comparison before and after crizotinib on evaluable patients

Patient no.	Pre-crizotinib			Post-crizotinib				
	ALK FISH% cells positive	ALK FISH pattern ^a	Abnormal ALK copy number/cell ^b	ALK FISH	ALK FISH% cells positive	ALK FISH pattern ^a	Abnormal ALK copy number/cell ^b	ALK change
4	78%	sR	1.2 sR	Positive	90%	sR	1.5 sR	Same
5	37%	split	0.4sR,sG	Positive	51%	split	0.5 sR,sG	Same
6	86%	split	0.8 sR,sG	Positive	70%	split	0.8 sR,sG	Same
7	28%	split	0.3 sR,sG	Positive	82%	split	1.5 sR,sG	CNG
8	48%	split	0.5 sR,sG	Positive	66%	split	2.2 sR,sG	CNG
9a	80%	sR	1.2sR	Negative	2%	NA		Loss
9b				Positive	56%	sR	0.9 sR	Same
10 ^c	28%	mix	0.3 sR, 0.2 sG	Positive	30%	mix	0.3 sR, 0.2 sG	Same
11	48%	split	0.5 sR,sG	Positive	56%	split	0.7 sR,sG	Same
12	26%	split	0.3 sR,sG	Negative	8%	NA		Loss
13 ^c	60%	split	0.6 sR, sG	Positive	48%	split	0.6 sR, sG	Same
14	68%	sR	1.2 sR	Positive	92%	sR	1.5 sR	Same

NOTE: Bold text denotes a significant result related to the mechanism of resistance.

^asR, single red; sG, single green; split, split red/green; mix, split red/green and single red.

^bRounded to the nearest tenth decimal.

^cPatients with intrinsic resistance.

produced resistance to crizotinib, the mutation encoding this substitution was generated in a cDNA encoding the E6a; A20 variant of *EML4-ALK*. Lentiviral vectors encoding wild-type *EML4-ALK* (E6a;E20) or the same cDNA encoding

G1269A, C1156Y, or L1196M substitutions or empty vector were introduced into Ba/F3 cells. Proliferation assays in the presence of increasing doses of crizotinib were conducted (Fig. 1C). The G1269A mutation induced crizotinib

Table 2. Molecular analysis of rebiopsy samples of evaluable patients

Patient no.	Mechanisms of resistance				
	ALK FISH	ALK FISH CNG	ALK domain sequence ^a	EGFR	KRAS
4	Positive	Negative	L1196M	WT ^a	WT ^a
5	Positive	Negative	L1196M	WT ^a	WT ^a
6	Positive	Negative	G1269A^b	WT ^{a,c}	WT ^{a,c}
7	Positive	Positive	G1269A	WT ^c	WT ^c
8	Positive	Positive	WT	WT ^a	WT ^a
9a	Negative	Negative	NA	L858R^{a,c}	WT ^{a,c}
9b	Positive	Negative	WT ^b	WT ^c	WT ^c
10 ^d	Positive/negative ^e	Negative	WT	ND	G12C^{c,e}
11	Positive	Negative	WT	WT ^a	G12V^a
12	Negative	Negative	WT	WT ^c	WT ^c
13 ^d	Positive	Negative	WT ^b	ND	ND
14	Positive	Negative	WT	WT ^a	WT ^a

NOTE: Bold text denotes the key mechanism(s) of resistance.

Abbreviations: NA, not available; WT, wild-type.

^aDirect sequencing.

^bHeterozygous for rs3795850 *ALK* SNP.

^cSNaPshot includes *APC*, *AKT1*, *BRAF*, *CTNNB1*, *EGFR*, *FLT3*, *JAK2*, *KIT*, *KRAS*, *MAP2K1 (MEK1)*, *NOTCH1*, *NRAS*, *PIK3CA*, *PTEN*, and *TP53*.

^dPatients with intrinsic resistance.

^eFrom patient-derived cell line with loss of *ALK* gene rearrangement by FISH or RT-PCR. The FFPE tissue was *ALK* FISH⁺.

resistance that was intermediate between the previously identified mutations, C1156Y and L1196M. Similar results were obtained when these constructs were introduced into the NIH3T3 cell line and colony formation was measured in soft agar (Supplementary Fig. S4). Consistent with the observed cell line resistance, ALK phosphorylation and phosphorylation of downstream effectors, extracellular signal-regulated kinase (ERK), STAT3, and AKT were preserved at higher doses of crizotinib in the G1269A mutant compared with wild-type *EML4-ALK* (Fig. 1D and E).

Preclinical and clinical evidence suggest that the gatekeeper mutation T790M in *EGFR* mutant NSCLC may provide a growth disadvantage compared with NSCLC with an *EGFR* mutation lacking T790M (24, 25). We therefore examined the relative fitness of the G1269A, C1156Y, and L1196M mutations compared with wild-type *EML4-ALK* (variant E6a;A20) in the Ba/F3 cell system (Fig. 1F). We did not detect a growth disadvantage for any of the resistant mutations compared with wild type. Indeed, the *EML4-ALK* constructs harboring resistance mutations induced increased proliferation compared with nonmutated *EML4-ALK* in the absence of crizotinib.

Copy number gain of the ALK gene rearrangement as a mechanism of crizotinib resistance

A gain in *ALK* gene fusion copy number has recently been implicated as a mechanism of resistance to crizotinib *in vitro* (26). In addition to standard FISH analysis for *ALK*, we measured the number of copies per cell of the *ALK* gene rearrangement before and after crizotinib treatment (15). Copy number gain (CNG) was defined as more than 2-fold increase in the mean of the rearranged gene per cell in the posttreatment specimen compared with the pretreatment specimen. Two patients showed a marked increase in abnormal signal copy number (#7 at 5-fold and #8 at >4-fold),


consistent with CNG of the *ALK* gene fusion (Table 1, Fig. 2A and B). The CNG in these 2 patients was due both to more copies of the *ALK* rearrangement per cell and more cells displaying the rearrangement pattern.

EGFR mutations as a mechanism of crizotinib resistance

Patient #9 underwent 2 separate biopsy procedures each of different lesions. The first was conducted after 61 days on crizotinib after the initial restaging scans showed stable disease, which was considered unusual given the responses seen in the majority of ALK-positive patients treated with crizotinib (6). This biopsy showed a lack of an *ALK* gene rearrangement by FISH (Fig. 2C). Further evaluation by direct sequencing showed the presence of an *EGFR* exon 21 mutation encoding the L858R substitution (Table 2, Supplementary Fig. S2B) that was not present in the initial transbronchial biopsy used to establish the ALK⁺ diagnosis (data not shown). The *EGFR* mutation on this specimen was confirmed by SNaPshot analysis (data not shown). Interestingly, a second biopsy conducted on a progressing liver lesion after 113 days on crizotinib did show an *ALK* gene rearrangement, but no evidence of an *ALK* domain mutation, an *EGFR* mutation, or of any other abnormal oncogenes as assessed by SNaPshot (Tables 1 and 2, data not shown). To confirm that all samples were indeed from the same patient, the original diagnostic biopsy and both rebiopsy samples were fingerprinted using short tandem repeat analysis, confirming the common genetic origin of the samples (data not shown).

Of note, patient #1, who underwent a post-crizotinib biopsy but had no evaluable material (Supplementary Table S1), showed the presence of an *EGFR* exon 20 mutation (S768I) in the pre-crizotinib biopsy sample in addition to the presence of an *ALK* gene rearrangement by FISH

Figure 2. ALK FISH pattern changes from pre- to post-crizotinib tumor samples. FISH analysis of patients #6 (A) and #7 (B) before crizotinib treatment (left) and after progression on crizotinib (right) shows a gain of split green (5') and red (3') *ALK* signals per each tumor cell. FISH analysis of patients #8a (C) and 11 (D) before crizotinib treatment (left) and after progression on crizotinib (right) shows loss of split green (5') and red (3') *ALK* signals.



analysis. This patient received erlotinib therapy for more than 9 months before discontinuing it and beginning crizotinib.

KRAS mutations as a mechanism for crizotinib resistance

Patient #10 received only 27 days of crizotinib before disease progression was evident (Supplementary Table S1). Testing of the rebiopsy sample showed a persistent *ALK*⁺ FISH test but no further molecular testing was carried out because the remainder of the tumor sample was used to initiate a cell line (Supplementary Fig. S5). Initial analysis of this cell line showed marked resistance to crizotinib in comparison to 2 known *EML4-ALK*⁺ NSCLC cell lines (Fig. 3A). FISH analysis of this cell line later showed no evidence of an *ALK* gene rearrangement and repeated RT-PCR analysis failed to show evidence of an *EML4-ALK* gene transcript (data not shown). SNaPshot analysis of the cell line showed the presence of a *KRAS* G12C mutation and this was confirmed by direct sequencing (Supplementary Fig. S3C). Given the short duration until progression, we asked whether this mutation was detectable in the pre-crizotinib sample. Direct sequencing of the microdissected pre-crizotinib biopsy,

which had not been previously analyzed for *KRAS*, showed the presence of the *KRAS* G12C mutation (Supplementary Fig. S3C).

Patient #11 experienced a partial response to treatment, before progression in the liver after 7 months, when a biopsy was carried out and showed persistence of an *ALK* gene rearrangement as well as a *KRAS* mutation encoding the G12V substitution (Tables 1 and 2; Supplementary Fig. S3D). Analysis of the diagnostic biopsy showed no evidence of a preexisting mutation in *EGFR* or *KRAS* (Supplementary Table S1).

In patient #11, we were unable to determine whether the *ALK* gene rearrangement and *KRAS* mutation occurred in the same or different tumor cells; whereas in the case of patient #10, given that an *ALK*-negative, *KRAS*-positive cell line could be generated from a lesion in whom both abnormalities were present in the biopsy this means that *ALK*- and *KRAS*-positive cells must have existed as separate subclones within the same tumor. To further explore whether acquisition of a *KRAS* mutation could serve as a direct mechanism of acquired resistance to crizotinib in *ALK*-positive cells, we asked whether expression of a mutant *KRAS* G12V could elicit crizotinib resistance in an *EML4-ALK*-positive cell line (H3122), which is normally sensitive to crizotinib. *KRAS* G12V was selected because it was the form observed in patient #11, where the coexistence in the same cells could not be formally evaluated. Mutant *KRAS* G12V or empty vector was introduced into H3122, and cell proliferation was measured after exposure to increasing doses of crizotinib (Fig. 3B). The *IC*₅₀ value of H3122 expressing *KRAS* G12V was not significantly different from H3122 harboring the empty vector.

Emergence of an *ALK* gene fusion-negative tumor

All post-crizotinib biopsy samples with evaluable tumor tissue underwent repeat *ALK* FISH testing. In patient #10, an *ALK* gene fusion was not observed in the cells that were propagated from the rebiopsied supraclavicular fossa lesion, which were later shown to be *KRAS* mutant. In patient #9, an *ALK* gene fusion was not observed in the rebiopsied supraclavicular fossa lesion, which was later shown to harbor and *EGFR* mutation. Patient #12 also lacked an *ALK* gene fusion as detected by FISH in the rebiopsy of the infraclavicular lymph node (Table 1, Fig. 2D). RT-PCR of the post-crizotinib sample from patient #12 using a multiplexed assay to detect different *EML4-ALK* variants also failed to show the presence of an *ALK* gene fusion (data not shown). Unlike with patients #10 and #11, no other abnormality was detected in the evaluated genes in this patient using the SNaPshot assay.

Unknown mechanisms of crizotinib resistance

Patients #13 and #14 showed the presence of an *ALK* gene rearrangement by FISH analysis after progression on crizotinib (Table 1). Patient #13 showed no evidence of *ALK* gene CNG or loss and no evidence of an *ALK* domain mutation. Patient #14 showed no evidence of *ALK* gene




Figure 3. Alternate activating oncogenes in patients with *ALK*⁺ NSCLC. A, H3122, H2228, and CUTO-1 cells (from patient #10) were treated with the indicated concentration of crizotinib and viable cells were measured after 72 hours and then plotted relative to untreated controls. B, H3122 cells with expression of *KRAS* G12V or empty vector were treated with the indicated concentration of crizotinib and viable cells were measured after 72 hours and then plotted relative to untreated controls.

CNG or loss, no evidence of an ALK domain mutation, and no evidence of an $EGFR$ or $KRAS$ mutation (Tables 1 and 2).

Discussion

Here, we describe the molecular mechanisms of resistance in a large series of patients with ALK^+ NSCLC with progression on crizotinib therapy. Previous studies have described the development of *in vitro* resistance mechanism using cell lines grown in the presence of crizotinib (26–29). Selected clinical cases of crizotinib resistance have been described, but without a denominator to estimate the frequency of the given abnormalities (12, 13). In this study, we successfully obtained molecular data on 11 of 14 rebiopsied patients with ALK^+ NSCLC with progression on crizotinib. A specific potential resistance mechanism was identified in 9 of these cases (Fig. 4A).

Precedent exists for the emergence of kinase domain mutations as mechanisms of resistance, most notably T315I in $BCR-ABL$ and T790M in $EGFR$ (7, 21, 22). We identified 4 patients (36%) with acquired resistance mutations in ALK . Two patients had the previously described L1196M mutation, in the classical gatekeeper

position homologous to T315I and T790M (12). L1196M levels were low in one patient but were confirmed by RFLP analysis (data not shown). Two patients showed a novel G1269A mutation. One of these patients also harbored a novel ALK gene fusion involving exon 6 of $EML4$ and exon 19 of ALK (Supplementary Fig. S3). All previously published ALK gene fusions involve exon 20 of ALK . Mutations at position G1269 have previously been identified using an *in vitro* mutagenesis screen (29). *In vitro* studies with G1269A show persistent ALK phosphorylation and downstream effector phosphorylation at higher doses of crizotinib than in the wild type. Decreased growth inhibition from crizotinib was also observed with G1269A relative to the wild type. Interrogation of the ALK crystal structure bound to crizotinib reveals G1269 to be critically situated in the ATP-binding pocket (Fig. 1A and B). Crizotinib binding in this pocket is unlikely to be able to tolerate larger amino acid substitutions in either G1269 or L1196. Replacement of the Leu side chain with a longer thioether side chain (L1196M) has been shown to significantly compromise the interaction with crizotinib (12). Similarly, a bulkier Ala in place of Gly1269 would preclude proper binding of the halogenated aromatic ring of crizotinib (Fig. 1A and B).




Figure 4. Relative frequencies of crizotinib resistance mechanisms in patients with ALK^+ NSCLC and models for potential mechanisms of alternate oncogene acquisition. A, the wedges represent different molecular mechanisms of resistance identified in patients with ALK^+ NSCLC in this study. The blue arc represents presumed or confirmed presence of an alternate oncogene. The yellow arc represents CNG. The red arc represents the presence of an ALK domain mutation. The grey wedge represents those patients where an ALK gene rearrangement was observed, but no mechanism of resistance was identified. *, inclusion of one patient with intrinsic resistance within this category. B, model #1 depicts the low-level presence of a second oncogenic driver in the same cell as an ALK gene rearrangement, which after treatment with crizotinib becomes the dominant clone. Model #2 depicts the presence of separate clonal populations, some with an ALK gene rearrangement as the driver and others with an alternate oncogene driver (e.g., $KRAS$ or $EGFR$). After treatment with crizotinib, the non- ALK clones become the dominant clone.

The observation that 4 of 10 resistant samples had *ALK* kinase domain mutation suggests that resistance mutations in *ALK*⁺ NSCLC will likely be a common mechanism of resistance to crizotinib, similar to that of EGFR-TKI resistance (9). However, unlike EGFR-TKI resistance in NSCLC, there seems to be a greater diversity of resistance mutations as 4 different mutations have now been identified in patients with *ALK*⁺ NSCLC (12, 13). This is reminiscent of patients with chronic myelogenous leukemia (CML) treated with imatinib, in which multiple different mutations in the ABL kinase domain have been identified (30). One can speculate that the kinase domain of EGFR may be more constrained given the presence of an existing activating mutation and may only be able to tolerate a very limited set of mutations that inhibit drug binding but still allow constitutive activation. In contrast, EML4-*ALK*, like BCR-ABL, has a native kinase domain structure, which may be able to tolerate a wider spectrum of resistance mutations that inhibit crizotinib binding but still allow constitutive activation. Consistent with this hypothesis is the *in vitro* data showing that the *ALK* resistance mutations studied here exhibited enhanced growth compared with the nonmutated EML4-*ALK* in an isogenic cell line. In contrast, EGFR T790M mutations confer impaired growth compared with cells carrying EGFR-activating mutations alone (25).

The existence of multiple different resistance mutations in *ALK* may have important clinical implications. First, testing for resistance mutations will require direct sequencing of multiple exons or a multiplexed assay looking for different specific mutations as data emerge. Second, the possibility of different mutations existing in the same patient has to be considered, increasing the difficulty of detecting each mutation. This is in addition to multiple other mechanisms that could affect detection including allelic dilution or a mixture of mutant and nonmutant cells in the biopsy sample (31, 32). Consequently, some resistance mutations may be missed and could conceivably be present in either of the patients in our study who retained *ALK* but appeared to have an unknown mechanism of resistance, or in the patient with CNG alone as their apparent mechanism of resistance. CNG alone has been described as a potential mechanism of resistance *in vitro*; however, this appeared to be a precursor state to the development of a resistance mutation (26). Finally, based on our own and others preclinical work different mutations seem to have different sensitivity rank orderings to crizotinib and this ordering may differ between *ALK* inhibitors (Fig. 1C and Supplementary Fig. S4; refs. 27, 29). Therefore, the optimal exposure of any *ALK* inhibitor in the TKI-naïve setting may differ from that in the acquired resistance setting. In addition, beyond dosing and toxicity issues, different *ALK* inhibitors may have to be prioritized depending on the specific mutation involved.

Seven of 11 patients in this study did not have *ALK* domain mutations, which led us to investigate alternate oncogenes as contributors to resistance. Prior studies have shown the coexistence of both an EGFR-activating mutation or a *KRAS* mutation and an *ALK* gene rearrangement in the

same tumor sample (13, 33–35). Here we describe 2 cases with a *KRAS* mutation (one of which was retrospectively detected in the pre-crizotinib specimen) and one patient with an EGFR-activating mutation at the time of resistance. An additional patient had a coexistent EGFR S768I mutation and an *ALK* gene rearrangement in the pre-crizotinib tumor sample, but no evaluable tissue after progression on crizotinib. The presence of EGFR and *ALK*, or *KRAS* and *ALK* in 2 of the pre-crizotinib tumor samples is consistent with results from a large cohort of *ALK*⁺ patients showing that 3 of 38 (8%) patients with *ALK*⁺ NSCLC also showed the presence of a *KRAS* or EGFR mutation (36).

The presence of multiple oncogenes in a tumor sample raises the question of whether these occur in the same tumor cells or different tumor cells and how these different oncogenic drivers arise (Fig. 4B). In EGFR mutant NSCLC with acquired resistance to EGFR-TKIs via *MET* gene amplification, *in vitro* data suggest that *MET* gene amplification occurs as a secondary event in the same tumor cell as depicted in model #1 (Acquisition of Second Oncogenic Driver; ref. 11). This can be detected at low levels in the biopsies taken before EGFR-TKI treatment (37). Treatment with an EGFR-TKI selects for those clones with an EGFR-activating mutation and *MET* amplification. We suggest a different model by which an alternate oncogene provides resistance to crizotinib in *ALK*⁺ NSCLC. In model #2 (Emergence of a Separate Oncogenic Driver), EGFR or *KRAS* mutations exist in separate subclonal populations that lack an *ALK* gene rearrangement. The presence of EGFR/*ALK* or *KRAS*/*ALK* double-positive results in biopsies before crizotinib treatment cannot distinguish model #1 from model #2. However, the outgrowth of a *KRAS* mutant, *ALK*-negative cell line from patient #10 confirms that model #2 can occur clinically. Similarly, although we did not have cell line data from patient #11 who manifested both *ALK* and *KRAS* positivity after progression, the fact that the introduction of the *KRAS* mutation seen in patient #11 into an *ALK*-positive cell line did not seem to alter their sensitivity to crizotinib *in vitro* argues against model #1, at least with regard to *KRAS* and *ALK*. In contrast to *KRAS*-activating mutations, introduction of an EGFR-activating mutation into H3122 cells *in vitro* is sufficient to induce crizotinib resistance, suggesting that in some situations, the acquisition of a second driver within the same *ALK*-positive cells could act as a mechanism of resistance clinically (model #1; ref. 13). However, as an EGFR-activating mutation was noted in progressing lesions without evidence of a persistent *ALK* gene rearrangement in patient #9, clinically, even for EGFR, model #2 can also exist. We also cannot exclude the presence of 2 separate primary cancers in this patient. Formally, whether separate oncogenic driver subclones arise completely independently, whether they share a common progenitor that lacks either driver and these drivers are developed independently as later events, or whether both drivers coexist within the same cell, and then one or other is lost in subclonal evolution is unclear.

Emergence of an *ALK* gene fusion–negative tumor was observed in one patient where another oncogenic driver was

not identified. Given the limited tumor sample and lack of a cell line in this patient, we were unable to query the presence of other oncogenic drivers beyond selected alleles of the genes evaluated in the SNaPshot panel. However, given that the emergence of an ALK-negative tumor was associated with definite evidence of a separate oncogenic driver in both patients #9 and #10, the assumption is that some other as yet unidentified oncogenic driver is present in these cells for them to persist. It should also be noted that in cases of the emergence of an ALK FISH-negative tumor that the percentage of positive cells was not zero, consistent with background noise in the break-apart FISH assay as described previously (38).

ALK CNG was observed in 2 patients. One patient had ALK CNG in conjunction with an ALK mutation and one had CNG without another detectable oncogene or mutation being present. The percentage of cells positive for a rearrangement was greater after CNG consistent with previous findings (15). A cell line that was partially crizotinib resistant *in vitro* apparently because of ALK gene fusion amplification alone was recently described (26). Increase of BCR-ABL copy number in CML serves as a precedent for this mechanism of resistance (39). In contrast, EGFR CNG has been more associated with EGFR-TKI sensitivity rather than resistance (40, 41).

We have described a series of patients with ALK-positive NSCLC with intrinsic or acquired resistance to crizotinib. Multiple different mechanisms seem to occur (Fig. 4). We would predict that in patients in whom ALK remains the dominant driver of their cancers (those with kinase domain mutations and ALK CNG), different therapies primarily directed toward the ALK protein, either TKIs or HSP90 inhibitors, may be beneficial (30, 42). However, when separate or second drivers occur—drug combinations or broader based treatments such as cytotoxic che-

motherapies may be required (13, 43). If understanding the heterogeneity present in NSCLC is important enough to direct patients to the correct initial therapy, then it is becoming clear that rebiopsying and reanalyzing cancers as they stop responding may be equally important as resistance is not occurring through a single mechanism (36). Fully understanding the basis and frequency of the different mechanisms of resistance to crizotinib that are emerging will help us to continue to exploit personalized medicine approaches when considering how to overcome crizotinib resistance in patients with ALK⁺ NSCLC in the future.

Disclosure of Potential Conflicts of Interest

R.C. Doebele has research grants from Pfizer, Eli Lilly, and ImClone. R.C. Doebele and M. Varella-Garcia have received speaker's fees from Abbott Molecular. R.C. Doebele, M. Varella-Garcia, D.R. Camidge, K.L. Kondo, A.J. Weickhardt, and D.L. Aisner have served as consultants for Pfizer. M. Varella-Garcia has served as a consultant for Abbott Molecular. D.R. Camidge has served as a consultant/advisory board member for Chugai, Ariad, and Eli Lilly. D.L. Aisner has served as a consultant for GlaxoSmithKline. No potential conflicts of interest were disclosed by the other authors.

Acknowledgments

The authors thank Barbara A. Helfrich and Christopher Korch for technical assistance and Delee A. Maxson for administrative assistance on the manuscript.

Grant Support

This research was supported by the University of Colorado Lung Cancer SPORE grant (P50CA058187) to R.C. Doebele, M. Varella-Garcia, and L.E. Heasley, by a research grant from Eli Lilly & Co. to R.C. Doebele and D.R. Camidge, and by funds from the Boettcher Foundation's Webb-Waring Biomedical Research Program to R.C. Doebele.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 14, 2011; revised December 9, 2011; accepted December 28, 2011; published OnlineFirst January 10, 2012.

References

- Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. *Nature* 2008;455:1069–75.
- Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355:2542–50.
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. *J Clin Oncol* 2008;26:3543–51.
- Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. *Science* 1994;263:1281–4.
- Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 2007;448:561–6.
- Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. *N Engl J Med* 2010;363:1693–703.
- Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005;2:e73.
- Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc Natl Acad Sci U S A* 2007;104:20932–7.
- Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011;3:75ra26.
- Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. *Proc Natl Acad Sci U S A* 2008;105:2070–5.
- Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 2007;316:1039–43.
- Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. *N Engl J Med* 2010;363:1734–9.
- Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. *Cancer Res* 2011;71:6051–60.

14. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. *J Clin Oncol* 2009;27:1667–74.
15. Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, et al. Correlations between the percentage of tumor cells showing an ALK gene rearrangement, ALK signal copy number and response to crizotinib therapy in ALK FISH positive non-small cell lung cancer. *Cancer* 2012 Jan 26 [Epub ahead of print].
16. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of ALK kinase in neuroblastoma. *Nature* 2008;455:971–4.
17. Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. *Clin Cancer Res* 2008;14:6618–24.
18. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. *EMBO Mol Med* 2010;2:146–58.
19. Doebele RC, Schulze-Hoepfner FT, Hong J, Chlenski A, Zeitlin BD, Goel K, et al. A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis. *Blood* 2009;114:4592–600.
20. Hong J, Doebele RC, Lingen MW, Quilliam LA, Tang WJ, Rosner MR. Anthrax edema toxin inhibits endothelial cell chemotaxis via Epac and Rap1. *J Biol Chem* 2007;282:19781–7.
21. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. *Science* 2001;293:876–80.
22. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. *Proc Natl Acad Sci U S A* 2005;102:7665–70.
23. Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E, et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. *Biochem J* 2010;430:425–37.
24. Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. *Clin Cancer Res* 2011;17:1616–22.
25. Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. *Sci Transl Med* 2011;3:90ra59.
26. Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. *Proc Natl Acad Sci U S A* 2011;108:7535–40.
27. Heuckmann JM, Holzel M, Sos ML, Heynck S, Balke-Want H, Koker M, et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. *Clin Cancer Res* 2011;17:7394–401.
28. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, et al. The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. *Cancer Res* 2010;70:10038–43.
29. Zhang S, Wang F, Keats J, Zhu X, Ning Y, Wardwell SD, et al. Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. *Chem Biol Drug Des* 2011;78:999–1005.
30. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. *Lancet* 2002;359:487–91.
31. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. *J Clin Invest* 2006;116:2695–706.
32. Yatabe Y, Matsuo K, Mitsudomi T. Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. *J Clin Oncol* 2011;29:2972–7.
33. Tiseo M, Gelsomino F, Boggiani D, Bortesi B, Bartolotti M, Bozzetti C, et al. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations. *Lung Cancer* 2011;71:241–3.
34. Martelli MP, Sozzi G, Hernandez L, Pettrossi V, Navarro A, Conte D, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. *Am J Pathol* 2009;174:661–70.
35. Kuo YW, Wu SG, Ho CC, Shih JY. Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation. *J Thorac Oncol* 2010;5:2039–40.
36. Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, et al. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). *J Clin Oncol* 29: 2011 (suppl; abstr CRA7506).
37. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, et al. Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. *Cancer Cell* 2010;17:77–88.
38. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. *Clin Cancer Res* 2010;16:5581–90.
39. le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. *Blood* 2000;95:1758–66.
40. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier AC, et al. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. *Ann Oncol* 2007;18:752–60.
41. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. *PLoS One* 2009;4:e4576.
42. Normant E, Paez G, West KA, Lim AR, Slocum KL, Tunkey C, et al. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models. *Oncogene* 2011;30:2581–6.
43. Camidge DR, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. *J Thorac Oncol* 2011;6:774–80.